GMP Warnings Follow Thin Corrective Action Evidence, Reliance On Contract Manufacturers
This article was originally published in The Rose Sheet
Executive Summary
FDA warning letters to VitaPurity and Morhaim Pharmalab remind the supplement firms they can’t rely on contract manufacturers and suppliers to meet FDA’s GMP practices, and that statements of corrective actions without proof are inadequate.